|
Turned
Down for Anti-CD11a Trial: Old Head Injury? Backstory:
Severe Relapse after Anti-cd11a
(Xanelim) Trial My (former)
derm had all kinds of research projects going, including such apparently
unrelated things as blood-hypertension and sinus problems.
I'd been a volunteer subject for him WAY back, for Neoral [cyclosporine
–Ed] — that's since been approved, at least in Canada, and of course
is outrageously expensive while they recover the R&D costs. So naturally he
wanted me on one of the early stages of the Anti-CD11a work (sorry, Ed, I
can never remember the "new improved" name).
This was back before they discovered that a half-strength starter
dose seemed to eliminate most of the killer-headache problems they'd
encountered in the earliest tests. He later told
me that Genentech had turned me down "because of your head
injury." To this day —
and I constantly kidded him about it while I was still seeing him — it's
not clear what the problem was. Was
I at risk of possibly more brain damage from it?
Or maybe they were afraid I’d throw their headache-incidence
stats out of whack. But my favorite
guess is that they weren't quite sure I was competent to sign the
consent-release agreement. -Best,
Mike B. ***** Ed’s
Response: Hah hah.
While your competency was surely not
at issue, your statistical propriety probably was.
Headaches definitely did surface as an issue in an earlier phase of
the anti-cd11a trials — see Anti-CD11a
Trial Sparked 3-Day Migraine — and mixing prior brain surgery into
the equation was probably deemed “asking for trouble,” hence you’re
not a likely guinea pig. I can’t help
but giggle, Mike, for as I prepare this for posting in the April-May ’02
update at FlakeHQ I’ve just seen a new TV commercial for Mike’s Hard
Lemonade (“Mike” being completely coincidental, I’m sure).
This new commercial is the one where this fellow has grown a
second, dwarfish, evil, ugly head, and this evil ugly head says, “I
didn’t know Mike made a hard lemonade” and grins pruriently at the
fetching feminine co-worker. In
the next scene two-heads and the co-worker are enjoying a Mike’s Hard Lemonade
somewhere outside the office. Anyway.... An update on
cyclosporine. Neoral was and is its initial product name by Novartis, the
manufacturer. But in the past
couple of years a generic version has been approved and is offered by Eon.
As far as I know, it’s just called “cyclosporine.”
I used it for the last several months on the regimen.
The only (significant) differences are it’s cheaper, and it’s
one helluva lot easier to get out of the packaging!
(Hey, when you’ve got severe nail psoriasis, that can be quite an
issue!) When/if
anti-CD11a makes it into the drug catalogs it will probably be as
“Xanelim,” at least at first. The
actual compound name (I guess it’s the compound name) is efalizumab
(I know, sounds like the name of a Hittite demon-god).
Manufacturers involved in the trials (that I am aware of) are
Genentech and Xoma (religious institutions that pay homage to Hittite
demon-gods?). Frankly, I’ve
heard so many horror stories about the trials, it will be a long time on
the market before I consider trying it. All things
considered, Mike, your old head injury may have come in handy.
Being turned down for this phase of the anti-cd11a trials might
have been okay.
At least you’re still here, still making me laugh (brain-damaged
or not). -Ed www.flakehq.com |